Longeveron Inc.
A clinical-stage biotech that turns young adults' bone-marrow stem cells into an injectable therapy, called Lomecel-B, being studied for aging-related conditions like frailty, Alzheimer's disease and a rare childhood heart defect. The company was founded in 2014 and spun out of the University of Miami's stem-cell institute. Its name blends "longevity" with "ever on"—a nod to its mission of helping people live longer, healthier lives.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| Mitchell P. Kopin | 13G/APassive | 9% | 2.94M | Aug 13, 2026 |
| Daniel B. Asher | 13G/APassive | 9% | 2.94M | Aug 13, 2026 |
| Intracoastal Capital LLC | 13G/APassive | 9% | 2.94M | Aug 13, 2026 |
| Integrated Core Strategies (US) LLC | 13GPassive | 5.2% | 1.55M | Aug 10, 2026 |
| Millennium Management LLC | 13GPassive | 5.2% | 1.55M | Aug 10, 2026 |
| Millennium Group Management LLC | 13GPassive | 5.2% | 1.55M | Aug 10, 2026 |
| Israel A. Englander | 13GPassive | 5.2% | 1.55M | Aug 10, 2026 |
| JANUS HENDERSON GROUP PLC | 13GPassive | 5.9% | 1.29M | May 15, 2026 |
| Lincoln Alternative Strategies LLC | 13G/APassive | 0% | 0 | Feb 10, 2026 |